The unique setting of ABIRISK, a study group that spans across different indications, will allow the comparison, for instance, of ex vivo phenotyping patterns with regards to their predictive value for ADA formation in several diseases, including MS, rheumatoid arthritis, and hemophilia (see text footnote 2). This evidence concerns the gene ADA and hemophilia.